ASX ANNOUNCEMENT

Vesting Conditions Met

Sydney 31 October 2018. Actinogen Medical ASX: ACW ('ACW' or 'the Company') advises the following vesting condition has been met on the Employee Share Plan Shares issued to Dr Bill Ketelbey:

Tranche	Number of Shares	Vesting Condition
Class J	3,000,000	Upon full recruitment of the Phase II study

The Company further advises that the vesting conditions on 1,600,000 unlisted 5 February 2021 $0.10 Options have been met and that 1,112,500 unlisted 5 February 2021 $0.10 Options have lapsed.

The Company has the following options on issue:

Expiry Date	Exercise Price	Options
30 November 2018	$0.02	27,750,000
31 March 2019	$0.06	147,876,233
5 February 2021	$0.10	3,559,298
1 December 2022	$0.10	1,500,000
24 March 2025	$0.10	5,000,000

ENDS

Actinogen Medical
Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
@BillKetelbey

Investor and Media Enquiries
Ben Walsh
WE Buchan
M: +61 411 520 012
E: bwalsh@we-buchan.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US$250bn, and is set to increase to US$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, is enrolling 174 patients at 25 research sites across Australia, the UK and the USA. Enrolment is expected to complete in Q4 2018, with top-line results expected in Q2 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.